Dendritic Cell Vaccination to Prevent Hepatocellular Carcinoma Recurrence After Liver Resection - Phase II Clinical Trial

Inclusion Criteria: * The patients have curative liver resection for primary or recurrent HCCs which are diagnosed by pathological figures, and the risk nomogram scores of tumor recurrence are $\\ge 101$ \[Hepatitis, score 57; platelet $\< 100\\times10\^3$, score 72; multiple tumors, score 69; cirrhosis, score 62; microvascular invasion, score 100; total tumor volume $\> 43.3\\text{cm}\^3$, score 90\]. * Age ≧20 years old and sign informed consent. * BCLC stage A-C * Child-Pugh sore ≤ 6 * Percentage of lymphocytes in peripheral blood ≧12%. * Performance status ECOG ≦2 * AST and ALT ≦ 5x upper limit of normal. * Platelet ≥ 80000/mm3 * WBC ≥ 3000/uL * RBC ≥ 2.5x106/uL * eGFR ≥ 30ml/min/1.73m2 * The patients must be disease-free after liver resection, which is confirmed by dynamic CT or MRI within 14 days. * The participants must have early stage or intermediate stage of HCC and receive liver resections to remove the tumors completely. * The participants must agree to harvest and preserve tumor specimens during operation. Exclusion Criteria: * Subjected having other malignancies except HCC are excluded. * Uncontrolled or clinically significant cardiac diseases. * Positive for HIV. * Active bacterial of fungal infections. * Prior chemotherapy within one month. * Use of other investigational drugs within one month. * Subjects with systemic steroid treatment within 14 days. * Subjects in the status of immune deficiency. * Subjects in the status of autoimmune diseases. * Subjects with long-term use of immunosuppressive agents. * Subjects with checkpoint inhibitor immunotherapy within one month. * Subjects with local regional therapy within one month.